Advaxis, Inc. Selects Inventiv Health Clinical To Conduct Clinical Trials Of Immunotherapy Candidates
5/29/2014 8:59:52 AM
PRINCETON, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, and inVentiv Health Clinical, a leading global clinical research organization (CRO), announced today that they have entered into a master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. The agreement is global and will focus initially on Advaxis's lead immunotherapy for cervical cancer, ADXS-HPV.
Help employers find you! Check out all the jobs and post your resume.
comments powered by